Capilliposide B blocks VEGF-induced angiogenesis in vitro in primary human retinal microvascular endothelial cells.
Biomed Pharmacother
; 133: 110999, 2021 Jan.
Article
en En
| MEDLINE
| ID: mdl-33227710
ABSTRACT
Abnormal angiogenesis is associated with intraocular diseases such as proliferative diabetic retinopathy and neovascular age-related macular degeneration, and current therapies for these eye diseases are not satisfactory. The purpose of this study was to determine whether capilliposide B (CPS-B), a novel oleanane triterpenoid saponin derived from Lysimachia capillipes Hemsl, can inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis signaling events and cellular responses in primary human retinal microvascular endothelial cells (HRECs). Our study revealed that the capilliposide B IC50 for HRECs was 8.5 µM at 72 h and that 1 µM capilliposide B specifically inhibited VEGF-induced activation of VEGFR2 and its downstream signaling enzymes Akt and Erk. In addition, we discovered that this chemical effectively blocked VEGF-stimulated proliferation, migration and tube formation of the HRECs, suggesting that capilliposide B is a promising prophylactic for angiogenesis-associated diseases such as proliferative diabetic retinopathy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Saponinas
/
Triterpenos
/
Neovascularización Fisiológica
/
Inhibidores de la Angiogénesis
/
Células Endoteliales
/
Factor A de Crecimiento Endotelial Vascular
/
Inductores de la Angiogénesis
Límite:
Humans
Idioma:
En
Revista:
Biomed Pharmacother
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos